Cancer despite immunosurveillance: immunoselection and immunosubversion.

Zitvogel L, Tesniere A, Kroemer G.
Nat Rev Immunol. 2006 Oct;6(10):715-27. Epub 2006 Sep 15.

Numerous innate and adaptive immune effector cells and molecules participate in the recognition and destruction of cancer cells, a process that is known as cancer immunosurveillance. But cancer cells avoid such immunosurveillance through the outgrowth of poorly immunogenic tumour-cell variants (immunoselection) and through subversion of the immune system (immunosubversion). At the early stages of carcinogenesis, cell-intrinsic barriers to tumour development seem to be associated with stimulation of an active antitumour immune response, whereas overt tumour development seems to correlate with changes in the immunogenic properties of tumour cells. The permanent success of treatments for cancer might depend on using immunogenic chemotherapy to re-establish antitumour immune responses.

URL: http://www.nature.com/nri/journal/v6/n10/abs/nri1936.html

Pub Med: http://www.ncbi.nlm.nih.gov/pubmed/16977338

created over 14 years ago (17 December 2009)    last modified over 13 years ago (28 September 2011)   [ RDF ]   [ RelFinder ]